Literature DB >> 19291600

Ormond's disease or secondary retroperitoneal fibrosis? An overview of retroperitoneal fibrosis.

M Heckmann1, M Uder, M A Kuefner, M C Heinrich.   

Abstract

Retroperitoneal fibrosis represents a rare inflammatory disease. About two thirds of all cases seem to be idiopathic (= Ormond's disease). The remaining one third is secondary and may be ascribed to infections, trauma, radiation therapy, malignant diseases, and the use of certain drugs. Up to 15 % of patients have additional fibrotic processes outside the retroperitoneum. The clinical symptoms of retroperitoneal fibrosis are non-specific. In sonography retroperitoneal fibrosis appears as a retroperitoneal hypoechoic mass which can involve the ureters and thus cause hydronephrosis. Intravenous urography and MR urography can demonstrate the typical triad of medial deviation and extrinsic compression of the ureters and hydronephrosis. CT and MRI are the modalities of choice for the diagnosis and follow-up of this disease. The lesion typically begins at the level of the fourth or fifth lumbar vertebra and appears as a plaque, encasing the aorta and the inferior vena cava and often enveloping and medially displacing the ureters. In unenhanced CT, retroperitoneal fibrosis appears as a mass that is isodense with muscle. When using MRI, the mass is hypointense in T 1-weighted images and of variable intensity in T 2-weighted images according to its stage: it may be hyperintense in early stages, while the tissue may have a low signal in late stages. After the administration of contrast media, enhancement is greatest in the early inflammatory phase and minimal in the late fibrotic phase. Dynamic gadolinium enhancement can be useful for assessing disease activity, monitoring response to treatment, and detecting relapse. To differentiate retroperitoneal masses, diffusion-weighted MRI may provide useful information.

Entities:  

Mesh:

Year:  2009        PMID: 19291600     DOI: 10.1055/s-2008-1027881

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  6 in total

1.  The potential role of modern US in the follow-up of patients with retroperitoneal fibrosis.

Authors:  Lars Kamper; Alexander Sascha Brandt; Hendrik Ekamp; Matthias Hofer; Stephan Roth; Patrick Haage; Werner Piroth
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

2.  Retroperitoneal fibrosis as a cause of positive FDG PET/CT.

Authors:  Amar Mehta; Todd M Blodgett
Journal:  J Radiol Case Rep       Date:  2011-07-01

3.  Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis.

Authors:  Lars Kamper; Alexander Sascha Brandt; Hendrik Ekamp; Nadine Abanador-Kamper; Werner Piroth; Stephan Roth; Patrick Haage
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

4.  (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease.

Authors:  Verena Ruhlmann; Thorsten Dirk Poeppel; Alexander Sascha Brandt; Johannes Grüneisen; Marcus Ruhlmann; Jens Matthias Theysohn; Michael Forsting; Andreas Bockisch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-11       Impact factor: 9.236

5.  Diffusion-weighted MRI in the follow-up of chronic periaortitis.

Authors:  L Kamper; P Haage; A S Brandt; W Piroth; N Abanador-Kamper; S Roth; H Ekamp
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

6.  [Infrarenal aortic ectasia in retroperitoneal fibrosis (RPF)].

Authors:  Hendrik Ekamp; Patrick Haage; Alexander Sascha Brandt; Stephan Roth; Werner Piroth; Lars Kamper
Journal:  Wien Med Wochenschr       Date:  2012-11-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.